DK2536722T3 - Bicycliske forbindelser og deres anvendelse som dual-c-src-/jak-inhibitorer - Google Patents
Bicycliske forbindelser og deres anvendelse som dual-c-src-/jak-inhibitorerInfo
- Publication number
- DK2536722T3 DK2536722T3 DK11709484.7T DK11709484T DK2536722T3 DK 2536722 T3 DK2536722 T3 DK 2536722T3 DK 11709484 T DK11709484 T DK 11709484T DK 2536722 T3 DK2536722 T3 DK 2536722T3
- Authority
- DK
- Denmark
- Prior art keywords
- src
- bicyclic
- relations
- dual
- jak inhibitors
- Prior art date
Links
- 229940122245 Janus kinase inhibitor Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Transplantation (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN415CH2010 | 2010-02-17 | ||
| PCT/IB2011/050669 WO2011101806A1 (en) | 2010-02-17 | 2011-02-17 | Bicyclic compounds and their uses as dual c-src / jak inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2536722T3 true DK2536722T3 (da) | 2014-05-26 |
Family
ID=43903941
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK11709484.7T DK2536722T3 (da) | 2010-02-17 | 2011-02-17 | Bicycliske forbindelser og deres anvendelse som dual-c-src-/jak-inhibitorer |
Country Status (28)
| Country | Link |
|---|---|
| US (2) | US8440679B2 (da) |
| EP (1) | EP2536722B1 (da) |
| JP (1) | JP2013519725A (da) |
| KR (1) | KR20120130294A (da) |
| CN (1) | CN102858770A (da) |
| AR (1) | AR089641A1 (da) |
| AU (1) | AU2011216895B2 (da) |
| BR (1) | BR112012020639A2 (da) |
| CA (1) | CA2789655A1 (da) |
| CU (1) | CU20120118A7 (da) |
| CY (1) | CY1115420T1 (da) |
| DK (1) | DK2536722T3 (da) |
| EA (1) | EA201290757A1 (da) |
| ES (1) | ES2470190T3 (da) |
| HR (1) | HRP20140437T1 (da) |
| IL (1) | IL221487A (da) |
| MX (1) | MX2012009482A (da) |
| NZ (1) | NZ602271A (da) |
| PH (1) | PH12012501654A1 (da) |
| PL (1) | PL2536722T3 (da) |
| PT (1) | PT2536722E (da) |
| RS (1) | RS53458B (da) |
| SA (1) | SA111320200B1 (da) |
| SG (1) | SG183329A1 (da) |
| SI (1) | SI2536722T1 (da) |
| SM (1) | SMT201400090B (da) |
| TW (1) | TW201130838A (da) |
| WO (1) | WO2011101806A1 (da) |
Families Citing this family (77)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2455382B1 (en) | 2005-12-13 | 2016-10-26 | Incyte Holdings Corporation | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors |
| EP3070090B1 (en) | 2007-06-13 | 2018-12-12 | Incyte Holdings Corporation | Use of salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h- pyrazol-1-yl)-3- cyclopentylpropanenitrile |
| SG176111A1 (en) | 2009-05-22 | 2011-12-29 | Incyte Corp | 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors |
| SA111320200B1 (ar) | 2010-02-17 | 2014-02-16 | ديبيوفارم اس ايه | مركبات ثنائية الحلقة واستخداماتها كمثبطات c-src/jak مزدوجة |
| PT3354652T (pt) | 2010-03-10 | 2020-07-20 | Incyte Holdings Corp | Derivados de piperidin-4-ilazetidina como inibidores de jak1 |
| RS54824B1 (sr) | 2010-05-21 | 2016-10-31 | Incyte Holdings Corp | Topikalna formulacija za inhibiciju jak-a |
| UA112517C2 (uk) | 2010-07-06 | 2016-09-26 | Новартіс Аг | Тетрагідропіридопіримідинові похідні |
| CA2818542A1 (en) | 2010-11-19 | 2012-05-24 | Incyte Corporation | Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors |
| US8754114B2 (en) | 2010-12-22 | 2014-06-17 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 |
| MY165963A (en) | 2011-06-20 | 2018-05-18 | Incyte Holdings Corp | Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors |
| UA111854C2 (uk) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
| ES2621255T3 (es) | 2012-03-12 | 2017-07-03 | Allergan, Inc. | Derivados de dihidropiridopirimidina y dihidronaftiridina como inhibidores de tirosina quinasa de especialmente vegf y pdgf |
| EP2825166A1 (en) | 2012-03-12 | 2015-01-21 | Allergan, Inc. | Method of treating ophthalmic conditions with kinase inhibitors |
| ES2704744T3 (es) | 2012-06-13 | 2019-03-19 | Incyte Holdings Corp | Compuestos tricíclicos sustituidos como inhibidores de FGFR |
| US9388185B2 (en) | 2012-08-10 | 2016-07-12 | Incyte Holdings Corporation | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors |
| CN113384546A (zh) | 2012-11-15 | 2021-09-14 | 因赛特公司 | 鲁索利替尼的缓释剂型 |
| US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
| EP2934532B1 (en) | 2012-12-20 | 2019-10-23 | Purdue Research Foundation | Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics |
| EP2951590A1 (en) | 2013-02-04 | 2015-12-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for assaying jak2 activity in red blood cells and uses thereof |
| WO2014138168A1 (en) | 2013-03-06 | 2014-09-12 | Incyte Corporation | Processes and intermediates for making a jak inhibitor |
| EA035095B1 (ru) | 2013-04-19 | 2020-04-27 | Инсайт Холдингс Корпорейшн | Бициклические гетероциклы в качестве ингибиторов fgfr |
| AU2014275643B2 (en) * | 2013-06-05 | 2018-08-09 | C&C Research Laboratories | Heterocyclic derivatives and use thereof |
| SG10201801069QA (en) | 2013-08-07 | 2018-03-28 | Incyte Corp | Sustained release dosage forms for a jak1 inhibitor |
| PL3636649T3 (pl) | 2014-01-24 | 2024-05-06 | Turning Point Therapeutics, Inc. | Diaryle makrocykliczne jako modulatory kinaz białkowych |
| KR102359214B1 (ko) | 2014-04-04 | 2022-02-07 | 델 마 파마슈티컬스 | 폐의 비소세포 암종 및 난소암을 치료하기 위한 디안하이드로갈락티톨 및 이의 유사체 또는 유도체 |
| US9498467B2 (en) | 2014-05-30 | 2016-11-22 | Incyte Corporation | Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1 |
| US9321766B1 (en) | 2014-10-06 | 2016-04-26 | Allergan, Inc. | Kinase inhibitors |
| US9296747B1 (en) | 2014-10-10 | 2016-03-29 | Allergan, Inc. | Piperidylpyrimidine derivatives as modulators of protein kinase inhibitors and of vascular endothelial growth factor receptor 2 |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| WO2016134294A1 (en) | 2015-02-20 | 2016-08-25 | Incyte Corporation | Bicyclic heterocycles as fgfr4 inhibitors |
| MX373169B (es) | 2015-02-20 | 2020-04-24 | Incyte Holdings Corp | Heterociclos bicíclicos como inhibidores de receptores del factor de crecimiento fibroblástico (fgfr). |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| ES2864839T3 (es) | 2015-07-02 | 2021-10-14 | Turning Point Therapeutics Inc | Macrociclos de diarilo quirales como moduladores de proteína quinasas |
| JP6917974B2 (ja) | 2015-07-06 | 2021-08-11 | ターニング・ポイント・セラピューティクス・インコーポレイテッドＴｕｒｎｉｎｇ Ｐｏｉｎｔ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | ジアリール大環状多形 |
| FI3733187T3 (fi) | 2015-07-21 | 2024-12-18 | Turning Point Therapeutics Inc | Kiraalinen diaryylimakrosykli ja sen käyttö syövän hoidossa |
| JP7282521B2 (ja) | 2016-04-08 | 2023-05-29 | パーデュー・リサーチ・ファウンデイション | Ｃａｒ ｔ細胞療法のための方法および組成物 |
| CN107459519A (zh) * | 2016-06-06 | 2017-12-12 | 上海艾力斯医药科技有限公司 | 稠合嘧啶哌啶环衍生物及其制备方法和应用 |
| TWI808958B (zh) | 2017-01-25 | 2023-07-21 | 美商特普醫葯公司 | 涉及二芳基巨環化合物之組合療法 |
| CN110612119B (zh) | 2017-02-07 | 2024-10-29 | 西雅图儿童医院（Dba西雅图儿童研究所） | 磷脂醚(ple)car t细胞肿瘤靶向(ctct)剂 |
| JP7178355B2 (ja) | 2017-02-28 | 2022-11-25 | エンドサイト・インコーポレイテッド | Ｃａｒ ｔ細胞療法のための組成物および方法 |
| WO2018167283A1 (en) | 2017-03-17 | 2018-09-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma associated neural remodeling |
| WO2018189335A1 (en) | 2017-04-13 | 2018-10-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| US10392367B2 (en) | 2017-06-01 | 2019-08-27 | Quentis Therapeutics, Inc. | IRE1 small molecule inhibitors |
| WO2018222917A1 (en) * | 2017-06-01 | 2018-12-06 | Quentis Therapeutics, Inc. | Ire1 small molecule inhibitors |
| CA3064837A1 (en) | 2017-06-01 | 2018-12-06 | Quentis Therapeutics, Inc. | Ire1 small molecule inhibitors |
| US11286264B2 (en) | 2017-07-28 | 2022-03-29 | Turning Point Therapeutics, Inc. | Macrocyclic compounds and uses thereof |
| AR113922A1 (es) | 2017-12-08 | 2020-07-01 | Incyte Corp | Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas |
| LT3728271T (lt) | 2017-12-19 | 2022-12-12 | Turning Point Therapeutics, Inc. | Makrocikliniai junginiai, skirti ligų gydymui |
| JP7549303B2 (ja) | 2018-01-22 | 2024-09-11 | エンドサイト・インコーポレイテッド | Ｃａｒ ｔ細胞の使用方法 |
| EA202091830A1 (ru) | 2018-01-30 | 2020-12-29 | Инсайт Корпорейшн | Способы и промежуточные соединения для получения ингибитора jak |
| SG11202007426XA (en) | 2018-02-06 | 2020-09-29 | Seattle Childrens Hospital Dba Seattle Childrens Res Inst | Fluorescein-specific cars exhibiting optimal t cell function against fl-ple labelled tumors |
| CN112105382A (zh) | 2018-02-23 | 2020-12-18 | 恩多塞特公司 | 用于car t细胞疗法的顺序方法 |
| MD3773593T2 (ro) | 2018-03-30 | 2024-10-31 | Incyte Corp | Tratament hidradenitei supurative utilizând inhibitori ai JAK |
| CR20200590A (es) | 2018-05-04 | 2021-04-26 | Incyte Corp | Formas sólidas de un inhibidor de fgfr y procesos para prepararlas |
| MA52493A (fr) | 2018-05-04 | 2021-03-10 | Incyte Corp | Sels d'un inhibiteur de fgfr |
| CN109336868A (zh) * | 2018-10-31 | 2019-02-15 | 南京先进生物材料与过程装备研究院有限公司 | 吲哚类stat3抑制剂及其制备方法 |
| CN109180657A (zh) * | 2018-10-31 | 2019-01-11 | 南京先进生物材料与过程装备研究院有限公司 | Stat3抑制剂的制备方法 |
| CN109485643A (zh) * | 2018-10-31 | 2019-03-19 | 南京先进生物材料与过程装备研究院有限公司 | 一种芴酮类stat3抑制剂及制备方法与应用 |
| CN109369627A (zh) * | 2018-10-31 | 2019-02-22 | 南京先进生物材料与过程装备研究院有限公司 | 芴酮类stat3抑制剂晶型a及制备方法 |
| CN109293641A (zh) * | 2018-10-31 | 2019-02-01 | 南京先进生物材料与过程装备研究院有限公司 | 一种芴类stat3抑制剂及其制备方法 |
| WO2020092015A1 (en) | 2018-11-02 | 2020-05-07 | University Of Rochester | Therapeutic mitigation of epithelial infection |
| WO2020185532A1 (en) | 2019-03-08 | 2020-09-17 | Incyte Corporation | Methods of treating cancer with an fgfr inhibitor |
| WO2021007269A1 (en) | 2019-07-09 | 2021-01-14 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| CN114761013A (zh) | 2019-09-27 | 2022-07-15 | 迪斯克医药公司 | 治疗骨髓纤维化和相关病症的方法 |
| WO2021067374A1 (en) | 2019-10-01 | 2021-04-08 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| TWI891666B (zh) | 2019-10-14 | 2025-08-01 | 美商英塞特公司 | 作為ｆｇｆｒ抑制劑之雙環雜環 |
| WO2021076728A1 (en) | 2019-10-16 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| EP4069696A1 (en) | 2019-12-04 | 2022-10-12 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| BR112022010664A2 (pt) | 2019-12-04 | 2022-08-16 | Incyte Corp | Derivados de um inibidor de fgfr |
| WO2021146424A1 (en) | 2020-01-15 | 2021-07-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| AU2021217003A1 (en) | 2020-02-04 | 2022-09-15 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Anti-dinitrophenol chimeric antigen receptors |
| WO2021231798A1 (en) | 2020-05-13 | 2021-11-18 | Disc Medicine, Inc. | Anti-hemojuvelin (hjv) antibodies for treating myelofibrosis |
| US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
| TW202304459A (zh) | 2021-04-12 | 2023-02-01 | 美商英塞特公司 | 包含ｆｇｆｒ抑制劑及ｎｅｃｔｉｎ－４靶向劑之組合療法 |
| EP4352059A1 (en) | 2021-06-09 | 2024-04-17 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| WO2022261159A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4349472A (en) | 1979-04-27 | 1982-09-14 | Schering Corporation | (S)-8(1-Adamantanecarbonyloxy)-7-chloro-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine |
| US6214966B1 (en) | 1996-09-26 | 2001-04-10 | Shearwater Corporation | Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution |
| AU763839B2 (en) * | 1998-05-26 | 2003-07-31 | Warner-Lambert Company | Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation |
| US6713454B1 (en) | 1999-09-13 | 2004-03-30 | Nobex Corporation | Prodrugs of etoposide and etoposide analogs |
| NZ526472A (en) * | 2000-12-21 | 2004-04-30 | Vertex Pharma | Pyrazole compounds useful as protein kinase inhibitors |
| AU2004279427B2 (en) * | 2003-10-08 | 2008-07-03 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
| JP2009525292A (ja) * | 2006-01-31 | 2009-07-09 | エフ．ホフマン−ラ ロシュ アーゲー | ７ｈ−ピリド［３，４−ｄ］ピリミジン−８−オン、それらの製造及びプロテインキナーゼ阻害剤としての使用 |
| WO2008077062A2 (en) | 2006-12-19 | 2008-06-26 | Board Of Regents, The University Of Texas System | Suppression of stat3 reactivation after src kinase inhibition to treat cancer |
| EP3070090B1 (en) | 2007-06-13 | 2018-12-12 | Incyte Holdings Corporation | Use of salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h- pyrazol-1-yl)-3- cyclopentylpropanenitrile |
| WO2009029998A1 (en) | 2007-09-06 | 2009-03-12 | Cytopia Research Pty Ltd | Retrometabolic compounds |
| GB2467670B (en) * | 2007-10-04 | 2012-08-01 | Intellikine Inc | Chemical entities and therapeutic uses thereof |
| US8183245B2 (en) | 2007-10-25 | 2012-05-22 | Merck Sharp & Dohme Corp. | Pyrazine substituted pyrrolopyridines as inhibitors of JAK and PDK1 |
| SA111320200B1 (ar) | 2010-02-17 | 2014-02-16 | ديبيوفارم اس ايه | مركبات ثنائية الحلقة واستخداماتها كمثبطات c-src/jak مزدوجة |
-
2011
- 2011-02-16 SA SA111320200A patent/SA111320200B1/ar unknown
- 2011-02-17 KR KR1020127023889A patent/KR20120130294A/ko not_active Withdrawn
- 2011-02-17 DK DK11709484.7T patent/DK2536722T3/da active
- 2011-02-17 AU AU2011216895A patent/AU2011216895B2/en not_active Expired - Fee Related
- 2011-02-17 MX MX2012009482A patent/MX2012009482A/es active IP Right Grant
- 2011-02-17 TW TW100105192A patent/TW201130838A/zh unknown
- 2011-02-17 NZ NZ602271A patent/NZ602271A/xx not_active IP Right Cessation
- 2011-02-17 SG SG2012060489A patent/SG183329A1/en unknown
- 2011-02-17 SI SI201130155T patent/SI2536722T1/sl unknown
- 2011-02-17 HR HRP20140437AT patent/HRP20140437T1/hr unknown
- 2011-02-17 RS RS20140277A patent/RS53458B/sr unknown
- 2011-02-17 PT PT117094847T patent/PT2536722E/pt unknown
- 2011-02-17 ES ES11709484.7T patent/ES2470190T3/es active Active
- 2011-02-17 BR BR112012020639A patent/BR112012020639A2/pt not_active IP Right Cessation
- 2011-02-17 CA CA2789655A patent/CA2789655A1/en not_active Abandoned
- 2011-02-17 WO PCT/IB2011/050669 patent/WO2011101806A1/en not_active Ceased
- 2011-02-17 JP JP2012553436A patent/JP2013519725A/ja not_active Ceased
- 2011-02-17 EA EA201290757A patent/EA201290757A1/ru unknown
- 2011-02-17 PL PL11709484T patent/PL2536722T3/pl unknown
- 2011-02-17 US US13/578,656 patent/US8440679B2/en not_active Expired - Fee Related
- 2011-02-17 PH PH1/2012/501654A patent/PH12012501654A1/en unknown
- 2011-02-17 AR ARP110100492A patent/AR089641A1/es unknown
- 2011-02-17 EP EP11709484.7A patent/EP2536722B1/en not_active Not-in-force
- 2011-02-17 CN CN2011800165418A patent/CN102858770A/zh active Pending
-
2012
- 2012-08-15 CU CU2012000118A patent/CU20120118A7/es unknown
- 2012-08-15 IL IL221487A patent/IL221487A/en not_active IP Right Cessation
-
2013
- 2013-01-14 US US13/741,019 patent/US8962637B2/en not_active Expired - Fee Related
-
2014
- 2014-06-03 CY CY20141100393T patent/CY1115420T1/el unknown
- 2014-07-10 SM SM201400090T patent/SMT201400090B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NZ602271A (en) | 2013-09-27 |
| JP2013519725A (ja) | 2013-05-30 |
| IL221487A (en) | 2014-11-30 |
| WO2011101806A1 (en) | 2011-08-25 |
| SMT201400090B (it) | 2014-09-08 |
| EA201290757A1 (ru) | 2013-04-30 |
| SI2536722T1 (sl) | 2014-10-30 |
| ES2470190T3 (es) | 2014-06-23 |
| AR089641A1 (es) | 2014-09-10 |
| HRP20140437T1 (hr) | 2014-08-29 |
| PT2536722E (pt) | 2014-05-26 |
| CY1115420T1 (el) | 2017-01-04 |
| US8440679B2 (en) | 2013-05-14 |
| EP2536722B1 (en) | 2014-04-16 |
| US8962637B2 (en) | 2015-02-24 |
| CU20120118A7 (es) | 2012-10-15 |
| RS53458B (sr) | 2014-12-31 |
| AU2011216895A1 (en) | 2012-09-27 |
| SG183329A1 (en) | 2012-09-27 |
| EP2536722A1 (en) | 2012-12-26 |
| CN102858770A (zh) | 2013-01-02 |
| TW201130838A (en) | 2011-09-16 |
| PH12012501654A1 (en) | 2018-02-07 |
| MX2012009482A (es) | 2012-11-29 |
| AU2011216895B2 (en) | 2015-11-05 |
| PL2536722T3 (pl) | 2014-11-28 |
| CA2789655A1 (en) | 2011-08-25 |
| KR20120130294A (ko) | 2012-11-30 |
| US20130012518A1 (en) | 2013-01-10 |
| HK1178897A1 (en) | 2013-09-19 |
| BR112012020639A2 (pt) | 2017-08-08 |
| US20130143895A1 (en) | 2013-06-06 |
| SA111320200B1 (ar) | 2014-02-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2536722T3 (da) | Bicycliske forbindelser og deres anvendelse som dual-c-src-/jak-inhibitorer | |
| HRP20181602T1 (hr) | Postupak pročišćavanja prokariotskih varijanti i fenilalanin-amonijak-lijaze | |
| DK2579877T3 (da) | Morpholinopyrimidiner og deres anvendelse til terapi | |
| DK2920149T3 (da) | 3-aminocycloalkyl-forbindelser som ror-gamma-t-inhibitorer og anvendelser deraf | |
| ME03766B (me) | Određeni amino-pirimidini, njihove kompozicije, i metode njihove upotrebe | |
| SMT201600135B (it) | Nuovi inibitori della s-nitrosoglutatione riduttasi | |
| SMT201600311B (it) | Inibitori di cdk | |
| DK3689878T3 (da) | 4-imidazopyridazin-1-yl-benzamider og 4-imidazotriazin-1-yl-benzamider som btk-inhibitorer | |
| DK3333188T3 (da) | Anti-NGF-antistoffer og deres anvendelse | |
| DK3590934T3 (da) | Pyrazolylquinoxalinkinasehæmmere | |
| SMT201500271B (it) | Inibitori di neprilisina | |
| IL225867B (en) | Coelenterazine substrates | |
| PL3299380T3 (pl) | Sposoby oczyszczania polipeptydów | |
| DK3608325T3 (da) | Polycykliske-carbamoylpyridonforbindelser og deres farmaceutiske anvendelse | |
| PL2649076T3 (pl) | Makrocyklowe inhibitory wirusów Flaviviridae | |
| DK2625295T3 (da) | High-throughput-immunsekvensering | |
| EP2777895A4 (en) | ROBOTIC HAND AND ROBOT | |
| DK2763665T3 (da) | Antimikrobielle sammensætninger og fremgangsmåder til anvendelse deraf | |
| DK3415157T3 (da) | N-acyldipeptidderivater og anvendelser deraf | |
| ME02952B (me) | Wnt antagonisti i metode tretiranja | |
| DK3392252T3 (da) | Pyrimido-pyridazinonforbindelser og deres anvendelse | |
| EP2732937A4 (en) | ROBOTIC HAND AND ROBOT | |
| HRP20160922T1 (hr) | Oligopeptidni spojevi i njihove uporabe | |
| IL250606A0 (en) | D2 antagonists, methods of synthesis and methods of use | |
| BR112014006291A2 (pt) | composição e utilização da composição |